Has the FDA Approved Any Vascepa Generics?
No, the FDA has not approved any generic versions of Vascepa (icosapent ethyl) as of the latest available data.[1]
What Is Vascepa and Why No Generics Yet?
Vascepa, made by Amarin, treats high triglycerides in adults with specific cardiovascular risks. Its brand exclusivity and patents block generics. The FDA granted it New Chemical Entity status in 2012 and 7-year orphan drug exclusivity for rare conditions, extended by further approvals like the 2020 REDUCE-IT trial expansion.[1][2]
When Do Vascepa Patents Expire?
Key U.S. patents on Vascepa's composition and use expire between 2034 and 2039, including method-of-use patents up to 2037-2039. Check DrugPatentWatch.com for the full list and challenges: DrugPatentWatch.com - Vascepa Patents.[1][3]
Are There Any ANDAs or Tentative Approvals?
Multiple generic makers, including Dr. Reddy's, Hikma, and Apotex, filed Abbreviated New Drug Applications (ANDAs). The FDA issued tentative approvals to some, like Hikma in 2023, but final approval awaits patent settlements or litigation outcomes. No generics launch until at least 2026 due to a 180-day exclusivity deal with Amarin.[1][4]
What About Authorized Generics or Competitors?
Amarin launched an authorized generic in 2020 through a deal with Dr. Reddy's, but this is not an FDA-approved independent generic—it's controlled by the brand maker. Competitors like generic Lovaza (omega-3 mix) exist but differ from Vascepa's pure EPA form.[2][5]
How Does This Compare to Other Fish Oil Drugs?
Unlike OTC fish oils, Vascepa requires a prescription for its purified icosapent ethyl. Generic Lovaza got FDA approval in 2016, but Vascepa's patents remain a barrier. Biosimilars aren't relevant as it's a small-molecule drug.[1]
Sources
[1]: FDA Orange Book - Vascepa
[2]: Drugs.com - Vascepa Patent Status
[3]: DrugPatentWatch.com - Vascepa
[4]: Amarin Press Releases on Settlements
[5]: FDA Approval History - Lovaza Generics